FCM Versus R-FCM Followed by R-Maintenance or Observation Only
Status:
Active, not recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The aim of this phase III trial is to assess the safety and efficacy of treatment with
rituximab in combination with FCM chemotherapy (R-FCM) versus FCM chemotherapy alone for
remission induction and to asses the safety and efficacy of rituximab maintenance versus
observation only after response to induction therapy. Both questions are addressed in way of
a prospective randomized comparison in patients with relapsed FL, MCL and LP lymphoma.